< Back to previous page

Project

Personalized immune therapy: FAP as a marker for resistance to immune checkpoint therapy in urothelial carcinomas.

(This research project aims to acquire dedicated knowledge on the protein 'Fibroblast activation protein alpha', further called 'FAP', in the context of personalized immune therapy. We will investigate whether FAP can be a biomarker for resistance to immunotherapy in urothelial carcinomas. In addition, we explore the presence of FAP in urine (as a non-invasive biological biomatrix) to monitor or predict the response to therapy for urothelial carcinomas.
Date:1 Sep 2019 →  31 Dec 2022
Keywords:BIOMARKERS
Disciplines:Cancer therapy, Biomarker discovery and evaluation not elsewhere classified, Anatomical pathology
Project type:Collaboration project